Novartis innovative drugs for heart failure are included in the 2019 medical insurance catalogue through negotiation, with the reimbursement rate up to 90%

November 28, 2019 / AP / -- on November 28, 2019, the national medical insurance bureau released the negotiation results of 2019 national medical insurance catalog, and 70 drugs were included in the national basic medical insurance, work injury insurance and maternity insurance drug catalog (2019 version) (hereinafter referred to as the medical insurance catalog), and determined the medical insurance payment standards of these drugs The new drugs involve chronic diseases, cancer, rare diseases and other fields The list published this time also includes Novartis innovative drug Novartis ® (sakubatrevalsartan sodium tablets), which is used to treat chronic heart failure As a class B drug in the medical insurance catalog, 70% - 90% can be reimbursed everywhere This also means that more than ten million heart failure patients in China have the basic guarantee of long-term standardized treatment With the help of medical insurance and innovative drugs, the risk of hospitalization and death of patients with heart failure is expected to further decline, and the quality of life is expected to further improve Tens of millions of people suffer from the threat of heart failure It is a long way to go for disease diagnosis and treatment China has become one of the countries with the largest group of heart failure patients in the world The prevalence of adult heart failure is as high as 1.3% [1], and there are at least 10 million patients As the end stage of all cardiovascular diseases, heart failure also has a huge "reserve force" Hypertension, coronary heart disease, valvular heart disease, diabetes, chronic kidney disease and other factors are all the inducing factors of heart failure With the aging of the population, these "potential" high-risk groups may face heart failure problems However, the current situation of heart failure diagnosis and treatment is not satisfactory: about 50% of heart failure patients died 5 years after diagnosis [2,3], and the survival rate is lower than that of many kinds of cancer In addition, the repeated hospitalization caused by heart failure brings heavy economic burden to patients, their families and society The data shows that the average number of inpatients in China is 2.4 times a year, and about 69% of them have the experience of rehospitalization within one year [4] The direct treatment cost is as high as 39000 yuan, nearly twice the annual per capita disposable income [5] It is imperative to improve the level of comprehensive diagnosis and treatment of heart failure and strengthen the long-term management of disease "Heart failure is not an incurable disease," said Liu Yuyang, a professor at Anzhen Hospital in Beijing If the patient finds some obvious symptoms of heart failure, such as: fatigue easily after activity, dyspnea when lying flat, lower extremity edema, decreased urine volume and other symptoms, they should go to the nearest heart failure center or regular hospital cardiology department for treatment in time, so as to achieve early detection and early treatment At the same time, the treatment of heart failure needs long-term management Even if the symptoms get better, patients need to follow the doctor's advice, standardize the medication, do not stop and reduce the medication at will, so as to reduce the hospitalization rate, improve the quality of life, and obtain better treatment outcome " In recent years, with the joint efforts of medical scientists, scholars and experts, China's heart failure field has made a lot of progress in standardized promotion and innovation of treatment methods According to the "2018 China heart failure diagnosis and treatment guidelines" updated in October 2018, the innovative drug angiotensin receptor enkephalinase inhibitor (Arni) is listed as one of the recommendations This update is mainly based on the outstanding clinical manifestations of Arni drugs: according to a clinical study, on the basis of standardized treatment of heart failure (Arni replaces the existing standard treatment scheme), it reduces the risk of cardiovascular death and hospitalization of heart failure patients by 20% [6] It is a great good news for people's livelihood that sakubaquvalsartan sodium tablets enter the medical insurance catalogue As a breakthrough innovative drug in the treatment of chronic heart failure in the past 20 years, sakubatrevalsartan sodium tablet is also the first Arni drug in the world, which is used for the treatment of patients with chronic heart failure (nyhai II-IV) It was first reviewed and listed by the State Food and Drug Administration in 2017, and has benefited 700000 patients with heart failure in China for two years "This time, sacubatrevalsartan sodium tablet was successfully included in the medical insurance catalog, which further confirmed that the national medical insurance access policy paid more attention to the multi-dimensional value benefits brought by drug treatment, such as: the innovation of drugs, whether they met the unmet clinical needs; and comprehensively considered the cost-effectiveness of drugs from the perspective of pharmacoeconomics." Liu Yuyang, Professor of Beijing Anzhen Hospital, said, "at the same time, this is also a great blessing for the majority of heart failure patients The reduction of drug burden will not only prompt patients to receive standardized drug treatment in time, but also enable more patients in the treatment to follow the guidelines to complete standardized treatment and obtain better treatment effect " Since August this year, the medicine to be negotiated was determined in the medical insurance catalogue After more than three months of negotiation cycle, sakubaquvalsartan sodium tablets have entered the national medical insurance catalogue, and can be reimbursed 70% - 90% according to class B medicine in the medical insurance catalogue According to the requirements of this national document, each city shall implement the negotiation results on January 1, 2020 For the specific implementation time and reimbursement policy of each city, please refer to the local specific implementation rules It is expected that with the implementation of the new medical insurance catalogue, innovative drugs can benefit more heart failure patients as soon as possible [1] Jcancer.2015apr15; 136 (8): 1921-30 [6] mcmurrayjj, packerm, Desaias, et al Angiotensinneprilysinhibition versusealaparinheart failure [J] Nengljmed, 2014371 (11): 993-1004 Doi: 10.1056/nejmoa1409077 37